Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 161 to 170 of 611 total matches.
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
-lactamases (ESBLs) and carbapenemases, particularly among Enterobacterales.1
Products that combine ...
The FDA has approved Exblifep (Allecra), a fixed-dose
combination of the cephalosporin cefepime and the
beta-lactamase inhibitor enmetazobactam, for IV
treatment of adults with complicated urinary tract
infections (cUTIs), including pyelonephritis, caused
by designated susceptible microorganisms (see
Spectrum of Activity). Exblifep is the first product that
contains enmetazobactam to be approved in the US.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):117-8 doi:10.58347/tml.2024.1707d | Show Introduction Hide Introduction
Palopegteriparatide (Yorvipath) for Hypoparathyroidism
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
), a parathyroid
hormone (PTH) 1-34 analog, has been approved
by the FDA for treatment of hypoparathyroidism ...
Palopegteriparatide (Yorvipath – Ascendis), a parathyroid
hormone (PTH) 1-34 analog, has been approved
by the FDA for treatment of hypoparathyroidism in
adults. The parathyroid hormone analog teriparatide
(Forteo, and others), which is approved for treatment
of postmenopausal osteoporosis, has been used off-label
for treatment of hypoparathyroidism.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):60-2 doi:10.58347/tml.2025.1726c | Show Introduction Hide Introduction
Talicia - A 3-Drug Combination for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
patient adherence to multidrug
regimens.1 When available, susceptibility testing
should be used to guide ...
The FDA has approved a fixed-dose combination
of omeprazole, amoxicillin, and rifabutin (Talicia –
RedHill) for treatment of Helicobacter pylori infection
in adults. Talicia is the first rifabutin-based product to
be approved for this indication.
Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis.1 The
GnRH ...
Oriahnn (Abbvie), a fixed-dose combination of the
gonadotropin-releasing hormone (GnRH) receptor
antagonist elagolix, the estrogen estradiol, and the
progestin norethindrone acetate copackaged with
elagolix alone, has been approved by the FDA for oral
treatment of heavy menstrual bleeding associated
with uterine leiomyomas (fibroids) in premenopausal
women. It is the first product to be approved in the
US for this indication. Elagolix (Orilissa) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis. The
GnRH receptor antagonist...
Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
antagonist elagolix in combination with estradiol and
norethindrone acetate, was approved earlier.1 ...
Myfembree (Myovant/Pfizer), an oral fixed-dose
combination of the gonadotropin-releasing hormone
(GnRH) receptor antagonist relugolix, the estrogen
estradiol, and the progestin norethindrone acetate,
has been approved by the FDA for management of
heavy menstrual bleeding associated with uterine
leiomyomas (fibroids) in premenopausal women. It is
the second product to be approved in the US for this
indication; Oriahnn, which contains the GnRH receptor
antagonist elagolix in combination with estradiol and
norethindrone acetate, was approved earlier. Relugolix
was approved for...
Zavegepant (Zavzpret) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
prevention.1,2 Atogepant (Qulipta), another oral
CGRP receptor antagonist, and four parenterally ...
The FDA has approved zavegepant nasal spray
(Zavzpret – Pfizer) for acute treatment of migraine
with or without aura in adults. Zavzpret is the first
nasal spray formulation of a calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant") to
become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8 doi:10.58347/tml.2023.1681c | Show Introduction Hide Introduction
Tofersen (Qalsody) for ALS
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
(ALS) in adults who
have a mutation in the superoxide dismutase 1
(SOD1) gene. About 2% of patients ...
Tofersen (Qalsody – Biogen), an intrathecally
administered antisense oligonucleotide, has received
accelerated approval from the FDA for treatment of
amyotrophic lateral sclerosis (ALS) in adults who
have a mutation in the superoxide dismutase 1
(SOD1) gene. About 2% of patients with ALS have
mutations in the SOD1 gene. Tofersen is the first drug
to be approved in the US that targets a genetic cause
of ALS. Accelerated approval of the drug was based
on the surrogate endpoint of a reduction in plasma
neurofilament light chain, which is considered likely
to predict clinical...
Med Lett Drugs Ther. 2023 Jul 24;65(1681):113-4 doi:10.58347/tml.2023.1681a | Show Introduction Hide Introduction
Omalizumab (Xolair) for Food Allergy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
, and chronic urticaria,1,2 has now
also been approved for use in conjunction with food
allergen avoidance ...
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also been approved for use in conjunction with food
allergen avoidance to reduce IgE-mediated food
allergic reactions caused by accidental exposure in
patients ≥1 year old. Omalizumab is the first drug to
be approved in the US to reduce allergic reactions to
more than one food. Palforzia, an oral peanut allergen
powder, was approved in 2020 to mitigate allergic
reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6 doi:10.58347/tml.2024.1699b | Show Introduction Hide Introduction
In Brief: Tafasitamab (Monjuvi) for Diffuse Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
on days 1 to 21 of each 28-day cycle) for up to
12 cycles, followed by tafasitamab alone until
disease ...
Tafasitamab-cxix (Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated
approval from the FDA for use in combination with
lenalidomide (Revlimid) for treatment of relapsed or
refractory diffuse large B-cell lymphoma (DLBCL),
not otherwise specified, including DLBCL arising from
low grade lymphoma, in adults who are not eligible
for autologous stem cell transplant. Accelerated
approval was based on overall response rates.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e133 doi:10.58347/tml.2023.1682d | Show Introduction Hide Introduction
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
in children
$1.704
1.504
14.80
189.505,6
Salicylates
Aspirin – generic
Bayer (Bayer)
325 mg tabs; 500 ...
View the Comparison Table: Some Nonopioid Analgesics for Pain